GL Pharm Tech Corp. (KOSDAQ:204840)

Market Cap	85.30B +11.5%
Revenue (ttm)	34.30B +37.7%
Net Income	307.33M
EPS	4.00
Shares Out	77.55M
PE Ratio	274.85
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	334,886
Average Volume	394,258
Open	1,107.00
Previous Close	1,130.00
Day's Range	1,090.00 - 1,127.00
52-Week Range	900.00 - 1,844.00
Beta	0.59
RSI	51.60
Earnings Date	Mar 18, 2026

About GL Pharm Tech

GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas. In addition, the company engages in developing new molecule entity pipeline products for dry eye disease. Further...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 33
• Stock Exchange: KOSDAQ
• Ticker Symbol: 204840

Financial Performance

In 2024, GL Pharm Tech's revenue was 26.05 billion, an increase of 0.06% compared to the previous year's 26.03 billion. Losses were -2.34 billion, -37.64% less than in 2023.